Cargando…

Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)

Staphylococcus aureus (S. aureus) is one of the well-known agents causing atopic dermatitis (AD) in susceptible individuals, and Staphylococcus epidermidis (S. epidermidis) produces class I thermostable bacteriocins that can selectively kill S. aureus, suggesting protective roles against AD. There i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, In-Taek, Yang, Miso, Kim, Hwa-Jung, Park, Jeong-Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168682/
https://www.ncbi.nlm.nih.gov/pubmed/32019186
http://dx.doi.org/10.3390/pathogens9020087
_version_ 1783523695108554752
author Jang, In-Taek
Yang, Miso
Kim, Hwa-Jung
Park, Jeong-Kyu
author_facet Jang, In-Taek
Yang, Miso
Kim, Hwa-Jung
Park, Jeong-Kyu
author_sort Jang, In-Taek
collection PubMed
description Staphylococcus aureus (S. aureus) is one of the well-known agents causing atopic dermatitis (AD) in susceptible individuals, and Staphylococcus epidermidis (S. epidermidis) produces class I thermostable bacteriocins that can selectively kill S. aureus, suggesting protective roles against AD. There is a large need for developing precise therapies only to target S. aureus and not to harm the beneficial microbiome. On the agar well diffusion assay, live planktonic S. epidermidis showed clear zones of inhibition of S. aureus growth, but heat-killed cells and cell-free supernatants did not show this. These results would lead us to hypothesize that cytoplasmic bacteriocin from S. epidermidis will be a promising agent to inhibit S. aureus growth. Therefore, we have extracted a novel thermolabile cytoplasmic bacteriocin from S. epidermidis using trichloroactic acid (TCA)/acetone precipitation method after cell lysis with a SDS-containing buffer. These bacteriocin selectively exhibited antimicrobial activity against S. aureus and methicillin-resistance Staphylococcus aureus (MRSA), presenting no active actions against S. epidermidis, E. coli, and Salmonella Typhimurium. The extracted cytoplasmic bacteriocin compounds revealed several diffuse bands of approximately 40–70 kDa by SDS-PAGE. These findings suggest that these cytoplasmic bacteriocin compounds would be a great potential means for S. aureus growth inhibition and topical AD treatment.
format Online
Article
Text
id pubmed-7168682
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71686822020-04-20 Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA) Jang, In-Taek Yang, Miso Kim, Hwa-Jung Park, Jeong-Kyu Pathogens Article Staphylococcus aureus (S. aureus) is one of the well-known agents causing atopic dermatitis (AD) in susceptible individuals, and Staphylococcus epidermidis (S. epidermidis) produces class I thermostable bacteriocins that can selectively kill S. aureus, suggesting protective roles against AD. There is a large need for developing precise therapies only to target S. aureus and not to harm the beneficial microbiome. On the agar well diffusion assay, live planktonic S. epidermidis showed clear zones of inhibition of S. aureus growth, but heat-killed cells and cell-free supernatants did not show this. These results would lead us to hypothesize that cytoplasmic bacteriocin from S. epidermidis will be a promising agent to inhibit S. aureus growth. Therefore, we have extracted a novel thermolabile cytoplasmic bacteriocin from S. epidermidis using trichloroactic acid (TCA)/acetone precipitation method after cell lysis with a SDS-containing buffer. These bacteriocin selectively exhibited antimicrobial activity against S. aureus and methicillin-resistance Staphylococcus aureus (MRSA), presenting no active actions against S. epidermidis, E. coli, and Salmonella Typhimurium. The extracted cytoplasmic bacteriocin compounds revealed several diffuse bands of approximately 40–70 kDa by SDS-PAGE. These findings suggest that these cytoplasmic bacteriocin compounds would be a great potential means for S. aureus growth inhibition and topical AD treatment. MDPI 2020-01-30 /pmc/articles/PMC7168682/ /pubmed/32019186 http://dx.doi.org/10.3390/pathogens9020087 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jang, In-Taek
Yang, Miso
Kim, Hwa-Jung
Park, Jeong-Kyu
Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title_full Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title_fullStr Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title_full_unstemmed Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title_short Novel Cytoplasmic Bacteriocin Compounds Derived from Staphylococcus epidermidis Selectively Kill Staphylococcus aureus, Including Methicillin-Resistant Staphylococcus aureus (MRSA)
title_sort novel cytoplasmic bacteriocin compounds derived from staphylococcus epidermidis selectively kill staphylococcus aureus, including methicillin-resistant staphylococcus aureus (mrsa)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168682/
https://www.ncbi.nlm.nih.gov/pubmed/32019186
http://dx.doi.org/10.3390/pathogens9020087
work_keys_str_mv AT jangintaek novelcytoplasmicbacteriocincompoundsderivedfromstaphylococcusepidermidisselectivelykillstaphylococcusaureusincludingmethicillinresistantstaphylococcusaureusmrsa
AT yangmiso novelcytoplasmicbacteriocincompoundsderivedfromstaphylococcusepidermidisselectivelykillstaphylococcusaureusincludingmethicillinresistantstaphylococcusaureusmrsa
AT kimhwajung novelcytoplasmicbacteriocincompoundsderivedfromstaphylococcusepidermidisselectivelykillstaphylococcusaureusincludingmethicillinresistantstaphylococcusaureusmrsa
AT parkjeongkyu novelcytoplasmicbacteriocincompoundsderivedfromstaphylococcusepidermidisselectivelykillstaphylococcusaureusincludingmethicillinresistantstaphylococcusaureusmrsa